Moonlake Immunotherapeutics (MLTX)

$17.18 +0.25 (1.48%)
Market Cap 1.21B
Revenue (ttm) 0.00
Net Income (ttm) -227.32M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.24
Volume 672,400
Avg Vol 1,201,420
Day's Range N/A - N/A
Shares Out 71.73M
Stochastic %K 21%
Beta 1.19
Analysts Strong Sell
Price Target $29.83

Company Profile

MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerla...

Industry: Biotechnology
Sector: Healthcare
Phone: 41 415108022
Address:
Dorfstrasse 29, Zug, Switzerland
Creisi
Creisi Apr. 25 at 3:50 PM
$MLTX Lou you are 100% correct. Everything about the development plan is catered specifically to maximizing M&A price. The FDA will ultimately decide Best in Class and that will come down to NRI calculations because it is all they accept in Phase 3 trials. Vela 52 week results are significantly better across the board when you project the numbers using NRI. MLTX's retention of an estimated 753 patients out of 838 is the highest ever for HS as SLK continued improvement is a magnet to those suffering with this debilitating disease!
0 · Reply
Creisi
Creisi Apr. 25 at 3:44 PM
$MLTX. @meadowlarkzac When you look at Brimzelx actual FDA submitted data at week 48 for HISCR50/75/90/100 the FDA received data is far weaker than UCB reports. FAR WEAKER! When I utilize the correct FDA required statistics; which drives Best in Class designation; SLK will be successful by a considerable margin at the 1 year mark. The rerating will drive price as analysts and hedge funds come to grips with reality. I have not chosen the most optimistic numbers I have chosen the most likely numbers. The primary driver for SLK is its NRI calculated results are very close to the 'observed results' as SLK is a magnet for patients... it works in delivering consistently more clear skin the longer you are on it... this is the single most important factor in determining efficacy by the FDA! I guarantee my projections are not high; they are moderate.
1 · Reply
Creisi
Creisi Apr. 25 at 1:49 PM
$MLTX This projection of $57.22 will occur 3 days after the Bela 52 week data is released. If it is released on May11th; then the share price will hit $57.22 on May 14th. The 3 day spread accounts for the late institutional and short sellers reaction on day 1 & 2 as they absorb what happened. The stock will rise to just under $40 on day 1. By day 3, 3 days after week 52 data release; it will hit $57.22.
3 · Reply
Creisi
Creisi Apr. 25 at 1:40 PM
$MLTX I have calculated what I expect the share price to reflect 3 days after the week 52 Vela data is released. I anticipate MLTX will report 754 retained patients of the original 838. Efficacy will beat Brimzelx across every metric and most notably in HiSCR100. The price will climb to $57.22 after analytic rewrites. This will happen on or about 3 days after data release as both short sellers and institutions will be a bit slower to react. This result is based on superior efficacy driven by high trial retention data establishing SLK as the most tolerable and efficacious treatment for HS.
1 · Reply
cranberry1
cranberry1 Apr. 25 at 1:11 PM
$MLTX
0 · Reply
MisterBean26
MisterBean26 Apr. 25 at 5:57 AM
$MLTX so, when am I rich? 🫵🏻🇨🇭🌍🇺🇸⏳
1 · Reply
midas7576
midas7576 Apr. 25 at 5:26 AM
$MLTX Short interest reducing: MLTX Short Interest MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX) Short Interest Settlement Date Short Interest Avg. Daily Share Volume Days to Cover 04/15/2026 6,654,522 1,569,884 4.238862 03/31/2026 7,757,169 997,078 7.779902 03/13/2026 7,313,594 799,861 9.143581 02/27/2026 7,036,421 1,607,440 4.377408 02/13/2026 7,271,326 1,052,124 6.911092 01/30/2026 7,017,037 1,415,292 4.958014 01/15/2026 7,182,036 5,630,446 1.275571
1 · Reply
Obidagreat
Obidagreat Apr. 25 at 3:45 AM
$MLTX
0 · Reply
Bigpapa46
Bigpapa46 Apr. 25 at 3:22 AM
$MLTX I just placed my vote!
0 · Reply
LouKojak
LouKojak Apr. 25 at 2:12 AM
$MLTX I'm 99.9999% certain moonlake doesn't go it along. US tarrifs will kill them. Market access will kill them. They have no economy of scale in operations. Being a drug developer is a completely different business to being a drug seller. I'm here for the buyout rumor.
2 · Reply
Latest News on MLTX
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting

Mar 28, 2026, 3:00 PM EDT - 27 days ago

MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting

MoonLake Immunotherapeutics Data Shows Phase 2 Success For Chronic Back Pain

Feb 23, 2026, 9:10 AM EST - 2 months ago

MoonLake Immunotherapeutics Data Shows Phase 2 Success For Chronic Back Pain

ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

Feb 10, 2026, 7:00 AM EST - 2 months ago

ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

IMA

MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day

Feb 2, 2026, 8:00 AM EST - 2 months ago

MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day

Helix Acquisition Corp. III Announces Closing of $172.5 Million Initial Public Offering, Including the Full Exercise of the Underwriter's Option to Purchase Additional Shares

Jan 27, 2026, 7:30 AM EST - 3 months ago

Helix Acquisition Corp. III Announces Closing of $172.5 Million Initial Public Offering, Including the Full Exercise of the Underwriter's Option to Purchase Additional Shares

Helix Acquisition Corp. III Announces Pricing of Upsized $150 Million Initial Public Offering

Jan 23, 2026, 7:30 AM EST - 3 months ago

Helix Acquisition Corp. III Announces Pricing of Upsized $150 Million Initial Public Offering

MoonLake Says FDA May Allow Skin Drug Filing Without New Trials, Stock Soars

Jan 8, 2026, 2:06 PM EST - 3 months ago

MoonLake Says FDA May Allow Skin Drug Filing Without New Trials, Stock Soars

MOONLAKE DECEMBER 15th DEADLINE: Bragar Eagel & Squire, P.C. Urgently Reminds MoonLake Immunotherapeutics Investors to Contact the Firm

Dec 15, 2025, 10:46 AM EST - 4 months ago

MOONLAKE DECEMBER 15th DEADLINE: Bragar Eagel & Squire, P.C. Urgently Reminds MoonLake Immunotherapeutics Investors to Contact the Firm

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

Dec 11, 2025, 10:08 AM EST - 4 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

DEADLINE NEXT WEEK: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Contact the Firm Before December 15, 2025

Dec 11, 2025, 8:54 AM EST - 4 months ago

DEADLINE NEXT WEEK: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Contact the Firm Before December 15, 2025

MLTX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

Dec 8, 2025, 1:23 PM EST - 4 months ago

MLTX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

MoonLake Immunotherapeutics (MLTX) Investors are Encouraged to Act before the Upcoming December 15 Securities Fraud Deadline – Contact BFA Law if You Lost Money

Dec 5, 2025, 8:18 AM EST - 5 months ago

MoonLake Immunotherapeutics (MLTX) Investors are Encouraged to Act before the Upcoming December 15 Securities Fraud Deadline – Contact BFA Law if You Lost Money

MoonLake's (MLTX) SLK Efficacy Claims Under Scrutiny After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority- Hagens Berman

Dec 5, 2025, 8:06 AM EST - 5 months ago

MoonLake's (MLTX) SLK Efficacy Claims Under Scrutiny After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority- Hagens Berman

MLTX Lawsuit: Hagens Berman Scrutinizing MoonLake's SLK Efficacy Claims After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority

Dec 4, 2025, 3:01 PM EST - 5 months ago

MLTX Lawsuit: Hagens Berman Scrutinizing MoonLake's SLK Efficacy Claims After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 15, 2025 in MoonLake Lawsuit - MLTX

Dec 4, 2025, 9:00 AM EST - 5 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 15, 2025 in MoonLake Lawsuit - MLTX

MLTX NEWS: MoonLake Immunotherapeutics Sued for Securities Fraud after Stock Plummets 90% -- Investors Notified to Contact BFA Law by December 15 Deadline

Dec 3, 2025, 7:46 AM EST - 5 months ago

MLTX NEWS: MoonLake Immunotherapeutics Sued for Securities Fraud after Stock Plummets 90% -- Investors Notified to Contact BFA Law by December 15 Deadline

Bragar Eagel & Squire, P.C. Urges Investors of Cepton, and MoonLake to Inquire About Their Rights Before Upcoming Deadlines

Dec 2, 2025, 5:29 PM EST - 5 months ago

Bragar Eagel & Squire, P.C. Urges Investors of Cepton, and MoonLake to Inquire About Their Rights Before Upcoming Deadlines

CPTN

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

Dec 1, 2025, 5:52 PM EST - 5 months ago

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

MLTX SHAREHOLDERS: MoonLake Immunotherapeutics Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by December 15

Dec 1, 2025, 3:18 PM EST - 5 months ago

MLTX SHAREHOLDERS: MoonLake Immunotherapeutics Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by December 15

MLTX LAWSUIT: BFA Law Reminds MoonLake Immunotherapeutics Investors the Company has been Sued for Securities Fraud and to Contact BFA Law by December 15 Deadline

Nov 30, 2025, 7:45 AM EST - 5 months ago

MLTX LAWSUIT: BFA Law Reminds MoonLake Immunotherapeutics Investors the Company has been Sued for Securities Fraud and to Contact BFA Law by December 15 Deadline

MoonLake Immunotherapeutics' (MLTX) Stock Crashes 90%, Triggers Lawsuit After Reported Phase 3 Trial Data for Sole Drug Candidate -- Hagens Berman

Nov 28, 2025, 5:50 PM EST - 5 months ago

MoonLake Immunotherapeutics' (MLTX) Stock Crashes 90%, Triggers Lawsuit After Reported Phase 3 Trial Data for Sole Drug Candidate -- Hagens Berman

MoonLake Immunotherapeutics' (MLTX) Reported Phase 3 Trial Data for Sole Drug Candidate, 90% Stock Crash Triggers Investor Suit -- Hagens Berman

Nov 27, 2025, 2:15 PM EST - 5 months ago

MoonLake Immunotherapeutics' (MLTX) Reported Phase 3 Trial Data for Sole Drug Candidate, 90% Stock Crash Triggers Investor Suit -- Hagens Berman

MOONLAKE NOTICE: MoonLake Immunotherapeutics (MLTX) Faces Securities Fraud Allegations after Stock Drops 90%, Investors Urged to Contact BFA Law

Nov 24, 2025, 6:08 AM EST - 5 months ago

MOONLAKE NOTICE: MoonLake Immunotherapeutics (MLTX) Faces Securities Fraud Allegations after Stock Drops 90%, Investors Urged to Contact BFA Law

MOONLAKE INVESTORS: MoonLake Immunotherapeutics (MLTX) has been Sued for Securities Fraud, Investors are Urged to Contact BFA Law

Nov 14, 2025, 6:08 AM EST - 5 months ago

MOONLAKE INVESTORS: MoonLake Immunotherapeutics (MLTX) has been Sued for Securities Fraud, Investors are Urged to Contact BFA Law

MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) DEADLINE ALERT Bernstein Liebhard LLP Reminds MoonLake Immunotherapeutics Investors of Upcoming Deadline

Nov 10, 2025, 8:15 AM EST - 5 months ago

MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) DEADLINE ALERT Bernstein Liebhard LLP Reminds MoonLake Immunotherapeutics Investors of Upcoming Deadline

MLTX STOCK NOTICE: MoonLake Immunotherapeutics Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by December 15 Deadline

Nov 10, 2025, 6:06 AM EST - 5 months ago

MLTX STOCK NOTICE: MoonLake Immunotherapeutics Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by December 15 Deadline

MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering

Nov 5, 2025, 7:11 AM EST - 6 months ago

MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering

MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab

Nov 5, 2025, 7:00 AM EST - 6 months ago

MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab

MLTX INVESTOR REMINDER: MoonLake Immunotherapeutics Investors may have been Affected by Fraud -- Contact BFA Law if You Suffered Losses

Nov 1, 2025, 7:08 AM EDT - 6 months ago

MLTX INVESTOR REMINDER: MoonLake Immunotherapeutics Investors may have been Affected by Fraud -- Contact BFA Law if You Suffered Losses

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

Oct 28, 2025, 9:51 AM EDT - 6 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

Creisi
Creisi Apr. 25 at 3:50 PM
$MLTX Lou you are 100% correct. Everything about the development plan is catered specifically to maximizing M&A price. The FDA will ultimately decide Best in Class and that will come down to NRI calculations because it is all they accept in Phase 3 trials. Vela 52 week results are significantly better across the board when you project the numbers using NRI. MLTX's retention of an estimated 753 patients out of 838 is the highest ever for HS as SLK continued improvement is a magnet to those suffering with this debilitating disease!
0 · Reply
Creisi
Creisi Apr. 25 at 3:44 PM
$MLTX. @meadowlarkzac When you look at Brimzelx actual FDA submitted data at week 48 for HISCR50/75/90/100 the FDA received data is far weaker than UCB reports. FAR WEAKER! When I utilize the correct FDA required statistics; which drives Best in Class designation; SLK will be successful by a considerable margin at the 1 year mark. The rerating will drive price as analysts and hedge funds come to grips with reality. I have not chosen the most optimistic numbers I have chosen the most likely numbers. The primary driver for SLK is its NRI calculated results are very close to the 'observed results' as SLK is a magnet for patients... it works in delivering consistently more clear skin the longer you are on it... this is the single most important factor in determining efficacy by the FDA! I guarantee my projections are not high; they are moderate.
1 · Reply
Creisi
Creisi Apr. 25 at 1:49 PM
$MLTX This projection of $57.22 will occur 3 days after the Bela 52 week data is released. If it is released on May11th; then the share price will hit $57.22 on May 14th. The 3 day spread accounts for the late institutional and short sellers reaction on day 1 & 2 as they absorb what happened. The stock will rise to just under $40 on day 1. By day 3, 3 days after week 52 data release; it will hit $57.22.
3 · Reply
Creisi
Creisi Apr. 25 at 1:40 PM
$MLTX I have calculated what I expect the share price to reflect 3 days after the week 52 Vela data is released. I anticipate MLTX will report 754 retained patients of the original 838. Efficacy will beat Brimzelx across every metric and most notably in HiSCR100. The price will climb to $57.22 after analytic rewrites. This will happen on or about 3 days after data release as both short sellers and institutions will be a bit slower to react. This result is based on superior efficacy driven by high trial retention data establishing SLK as the most tolerable and efficacious treatment for HS.
1 · Reply
cranberry1
cranberry1 Apr. 25 at 1:11 PM
$MLTX
0 · Reply
MisterBean26
MisterBean26 Apr. 25 at 5:57 AM
$MLTX so, when am I rich? 🫵🏻🇨🇭🌍🇺🇸⏳
1 · Reply
midas7576
midas7576 Apr. 25 at 5:26 AM
$MLTX Short interest reducing: MLTX Short Interest MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX) Short Interest Settlement Date Short Interest Avg. Daily Share Volume Days to Cover 04/15/2026 6,654,522 1,569,884 4.238862 03/31/2026 7,757,169 997,078 7.779902 03/13/2026 7,313,594 799,861 9.143581 02/27/2026 7,036,421 1,607,440 4.377408 02/13/2026 7,271,326 1,052,124 6.911092 01/30/2026 7,017,037 1,415,292 4.958014 01/15/2026 7,182,036 5,630,446 1.275571
1 · Reply
Obidagreat
Obidagreat Apr. 25 at 3:45 AM
$MLTX
0 · Reply
Bigpapa46
Bigpapa46 Apr. 25 at 3:22 AM
$MLTX I just placed my vote!
0 · Reply
LouKojak
LouKojak Apr. 25 at 2:12 AM
$MLTX I'm 99.9999% certain moonlake doesn't go it along. US tarrifs will kill them. Market access will kill them. They have no economy of scale in operations. Being a drug developer is a completely different business to being a drug seller. I'm here for the buyout rumor.
2 · Reply
zizozizzy
zizozizzy Apr. 25 at 1:38 AM
$MLTX do takeover offers usually happen post 52 wk results or post FDA submission?
1 · Reply
Rockybhai7239
Rockybhai7239 Apr. 25 at 1:02 AM
$MLTX reach higher levels Target pooled HiSCR100 Responderneed Additional patients needed 35% ~143 +19 36% ~147 +23 38% ~155 +31 40% ~164 +40 Key point Because pooled HiSCR90 is around ~38%, and pooled HiSCR100 is around ~30%, roughly 8% of patients are already sitting in the 90–99% improvement zone. 8% of 409 = ~33 patients. So mathematically, getting from 30% → 35–38% HiSCR100 is very realistic if a portion of those HiSCR90 patients convert to complete clearance by Week-52.
0 · Reply
cranberry1
cranberry1 Apr. 24 at 11:48 PM
$MLTX
0 · Reply
Modern_portholio_theory
Modern_portholio_theory Apr. 24 at 9:08 PM
$MLTX getting close everyone only 5 full weeks until start of june
1 · Reply
CknSalad
CknSalad Apr. 24 at 7:45 PM
$MLTX can anybody give a tl;dr what we are voting on? I got the time to vote on my mailbox.
1 · Reply
Creisi
Creisi Apr. 24 at 7:37 PM
$MLTX This is really bad. 57% of all patients completely failed Brimzelx therapy by week 96. 57% is a massive number of failures; yet they claim a HiSCR75 of over 7 of 10 in their own released Newswire! They claim 8 of 10 achieved HiSCR50 and 4 of 10 achieved HiSCR100. None of these numbers are even remotely possible and a grade 2 student can tell you that. They paid patients several thousand dollars each, told them they were taking the most effective drug for their HS after week 16, and yet 57% quit because the drug failed to address their debilitating disease. Couldn't stand it any longer! That is a massive red flag for Brimzelx and confirms UCB has zero ethics! Now I know why the FDA despise UCB; they're liars that bury the truth behind creative falsified data releases.
1 · Reply
Mr_GA
Mr_GA Apr. 24 at 7:17 PM
$MLTX
1 · Reply
Shaybe16569
Shaybe16569 Apr. 24 at 7:13 PM
$MLTX atleast a close above 17😂
0 · Reply
Creisi
Creisi Apr. 24 at 7:07 PM
$MLTX Here's UCB's link to their PR Newswire... 100% creative numerical bullshit. Not a single fucking mention of the 57% of patients that dropped out because the drug wasn't working for one reason or another... NOT A FUCKIN' WORD ABOUT THEM INSTEAD THEY JUST OMIT THEM LIKE THEY DO NOT EVEN EXIST. https://www.ucb.com/newsroom/press-releases/article/ucb-announces-late-breaking-two-year-data-for-bimzelxrvbimekizumab-in-moderate-to-severe-hidradenitis-suppurativa-at-eadv-2024 That's called lying, not marketing! These are real people lthey're putting that shit into. People that require benefit, not expense and bullshit. 6 out of 10 patients told them it caused more harm than benefit yet they bury that evidence from the public and tout it as Best in Class. Their results at 2 years is a reason to abandon the drug, NOT celebrate it. Only a fuckin' arsehole would promote this garbage.
1 · Reply
LouKojak
LouKojak Apr. 24 at 7:00 PM
$MLTX it was never supposed to go to $16.60... someone sold without the cartel's permission.
1 · Reply
Obidagreat
Obidagreat Apr. 24 at 6:58 PM
$MLTX
0 · Reply
Creisi
Creisi Apr. 24 at 6:54 PM
$MLTX Look if anything I'm being kind d to ICB and Brimzelx. They're going to go through a world of hurt when SLK launches and the FDA starts a crackdown on their marketing bullshit. That type of bullshit may fly in Belgium, but it won't fly around here. I think I might take a few weeks, talk to my friend at the FDA and then find out if they should take a look at the bullshit UCB is telling prescribers and patients about their shitty drug, Brimzelx. HiSCR75 at week 96 of 77.1%. What a pile of shit. HiSCR75 of 33.9% is the exact actual result. Sickening fuckin' deceptive bullshit.
0 · Reply